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Multiple sclerosis is a chronic disorder of the central nervous system, characterized by 
inflammation and axonal degeneration. All current therapies modulate the peripheral 
immune system. Treatments for patients in the progressive phase of the disease, which is 
characterized by axonal degeneration, are lacking. Many MS researchers believe that early 
and strong suppression of inflammation prevents axonal degeneration. However, so far 
strong immunosuppressive treatments failed to stop disease progression. 
In 2004 a hypothesis was presented in which the lack of the beta-2 adrenergic receptor on 
astrocytes of patients with MS might explain both the inflammatory responses and the 
progressive axonal degeneration. The loss of beta-2 adrenergic receptors on astrocytes 
reduces the formation of intracellular cAMP which 1) enables astrocytes to express 
interferon gamma induced MHC-2 and co-stimulatory B7 molecules, which turns 
astrocytes into antigen presenting cells, and 2) decreases astrocyte lactate production that is 
transported to axons as energy source. 
If the hypothesis holds true, drugs that are able to elevate intracellular cAMP might be 
beneficial for patients with MS. These drugs might reduce both inflammation as axonal 
degeneration in MS. Since fluoxetine is able to increase cAMP signalling in astrocytes this 
drug was chosen to study in patients with MS.  
 
The aim of this thesis was to study effects of fluoxetine in patients with MS. Since 
symptomatic disease activity in MS is infrequent and unpredictable, effects of medication 
are difficult to measure on clinical grounds alone. With MRI different pathophysiological 
features of MS can be visualized noninvasively, and disease activity can be easily 
monitored. We evaluated the use of MRI to monitor treatment and used a number of MRI 
techniques to study effects of fluoxetine in patients with MS.  
 
In the first part of this thesis we reviewed the effect of fluoxetine on neurological disorders 
(Chapter 2). Fluoxetine elevates neurotrophic factors, increases glycogenolysis in 
astrocytes, and blocks voltage gated calcium and sodium channels, which all might prevent 
axonal loss. Although we found many studies evaluating the use of fluoxetine for 
depression in neurological disorders, no well-designed studies were available that looked at 
effects of fluoxetine on neurological function.  
 
In the second part of this thesis we performed several studies using conventional MRI. In 
chapter 3 we showed in a double-blind, placebo-controlled study that MS patients using 
fluoxetine have a tendency to have less enhancing lesions on MRI, which is a surrogate 
marker for inflammation. Effects became more apparent after 8 weeks of treatment, which 
is in line with the time it takes for fluoxetine to reach stable plasma levels and to have 
antidepressant effects. Patients using fluoxetine also had less frequent MRI scans with 
enhancing lesions. These results must be confirmed in larger studies before fluoxetine can 
get an application in clinical practice. In chapter 4 different techniques to measure brain 
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atrophy were compared. Except for corpus callosum area all atrophy measurements were 
moderately to strongly correlated. Brain parenchymal fraction might be best to use in 
future MS studies. Next, we wondered what the long term relevance is of measuring T2 
lesions and atrophy in patients with MS. To answer this question we re-evaluated all 
available cerebral MRI scans of MS patients that were performed before 1997 at our clinic. 
The clinical follow-up data of all patients are registered in the Groningen MS-database. In 
chapter 5 we showed that more T2 lesions are an independent predictor for the onset of 
secondary progression. This is supported by our findings in chapter 6, which showed that 
T2 lesions are predictive for earlier progression of disability in relapsing remitting MS. 
However, in primary and secondary progressive MS the number of T2 lesions doesn’t have 
an influence on the progression of disability.  
 
In the third part of our thesis we performed several studies with ¹H-MRS. We studied 
cerebral lactate formation in healthy persons after performing a motor task (chapter 7). 
Lactate is produced by astrocytes and transported to axons as fuel during intense neural 
activity. According to our hypothesis, the astrocytic beta-2 adrenergic receptor defect in 
MS would impair the production of lactate in astrocytes. However, we could not detect 
cerebral lactate in healthy persons and we concluded that this activation study is not 
appropriate to investigate the lactate metabolism in MS patients. In chapter 8 we looked at 
the reproducibility of N-acetylaspartate/Creatine (NAA/Cr) after 4 weeks in clinically 
stable MS patients. NAA/Cr is regarded as a marker of axonal function and may be a 
suitable marker for axonal degeneration. Good surrogate markers are valid and 
reproducible. We showed that NAA/Cr is well reproducible after 4 weeks. The use of 
NAA/Cr in MS trials can thus be recommended. In chapter 9, we described an increase in 
NAA/Cr after two weeks of treatment with fluoxetine in an open study of 11 patients with 
relapsing remitting and secondary progressive MS. This supports possible beneficial 




Fluoxetine is cheap, world-wide available, taken orally, and safe to use long-term. This 
thesis provides a theoretical basis for the use of fluoxetine as disease modifying therapy in 
patients with MS. It contains two studies showing positive effects of fluoxetine on cerebral 
MRI measurements in patients with MS. Since these studies were small, had a maximum 
follow-up time of six months and did not use clinical endpoints, the prescription of 
fluoxetine as disease modifying therapy can yet not be advised. However, this thesis 
justifies and encourages further studies with fluoxetine in patients with MS.  
In patients with relapses a new phase 2 study could show whether the trend towards 
improvement we observed is reproducible. It should have the cumulative number of 
enhancing lesions as primary outcome measure and focus on effects of fluoxetine after 8 
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weeks of treatment. The launch of a large, multi-center trial, evaluating the effect of 
fluoxetine on clinical exacerbations in MS, can also be considered. Since many patients 
with exacerbations are treated with interferon-beta or glatiramer acetate and it is 
unethically to withhold patients of treatment for several years, a study using fluoxetine as 
add-on treatment to current immunomodulating therapy would be the way to go. 
The effect of fluoxetine on clinical progression in primary and secondary progressive MS 
is currently investigated in a small randomized, placebo-controlled study at the University 
Medical Center Groningen. Taking into account the lack of effective treatment in the 
progressive phase of the disease, the start of a larger trial in patients with progressive forms 
of MS is an interesting option. 
The effects of fluoxetine on disease activity support the hypothesis that enhancing cAMP 
in astrocytes might be beneficial for patients with MS. Studies with drugs, other than 
fluoxetine, that are able to enhance cAMP in astrocytes, can also be encouraged in patients 
with MS. 
 
The cumulative number of new enhancing lesions and number of new T2 lesions on 
cerebral MRI scans is frequently used as surrogate marker for inflammatory disease 
activity in MS studies. However, the clinical relevance of suppressing these lesions is 
unclear. The finding that more T2 lesions on cerebral MRI scans increase the risk of 
becoming secondary progressive in patients with relapsing remitting MS, indicates a 
relationship between the number of T2 lesions and secondary progression. Further studies 
must show whether suppression of new T2 lesions by immunomodulating therapies delays 
the onset of secondary progression. In patients with progressive forms of MS the number 
of T2 lesions does not predict the time to progression of disability, suggesting that T2 
lesions have no influence on progression of disability in progressive forms of MS. 
Monitoring new T2 lesions in follow-up studies can show whether increases in T2 lesions 
are associated with progression of disability. Currently measurement of T2 lesions in 
clinical trials of progressive forms of MS seems not useful. 
Brain atrophy is a surrogate marker for axonal degeneration and is increasingly used in MS 
trials. Although the different MRI derived atrophy measurements are strongly correlated, 
BPF might be best to use in new studies. 
New MRI techniques show abnormalities in grey and white matter that looks normal on 
conventional MRI. These techniques might provide better surrogate markers for disease 
activity than conventional MRI measurements. Of these, the use of MR Spectroscopic 
derived NAA/Cr can be recommended as marker for axonal function. With diffusion tensor 
imaging and magnetization transfer imaging it is possible to quantify cerebral white and 
grey matter structures. The importance of grey matter pathology is increasingly recognized 
and is visualized with three-dimensional (3D) double inversion recovery and T1-weighted 
3D spoiled gradient-recalled echo sequences. Although technically challenging, the use of 




We were unable to measure lactate formation with proton MR Spectroscopy. Phosphorus 
MR Spectroscopy is another technique that provides information on energy compounds 
like phosphocreatine (PCr) and adenosine triphosphate (ATP) in the CNS, and might be a 
suitable method to measure cerebral energy metabolism in MS. 
All techniques discussed should be further investigated for their suitability as surrogate 
marker for current and past disease activity in MS. Reproducibility and validity studies are 
warranted. All can be considered in new trials evaluating the use of fluoxetine in multiple 
sclerosis. 
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